Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Completed
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Relapsed Multiple Myeloma
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Completed
The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2017
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Myeloma
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Completed
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2017
Locations: Florida Cancer Specialists, Ft. Myers, Florida
Conditions: Multiple Myeloma
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
Completed
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more ef... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/15/2017
Locations: Broward Health Medical Center, Fort Lauderdale, Florida +12 locations
Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
Terminated
Open label, single-arm phase II study of avastin combined with fluorouracil, doxorubicin and streptozocin administered in 28-day cycles. Treatment will continue until progression of disease, or until withdrawal due to toxicity, or up to a maximum of 12 cycles (48 weeks). In order to reduce the risk of cardiac toxicity, doxorubicin will be administered for a maximum of 8 cycles. If disease has not progressed after 12 cycles of treatment, avastin monotherapy will continue until disease progression... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Pancreatic Cancer
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Completed
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: Not set, Boca Raton, Florida +4 locations
Conditions: Multiple Myeloma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.
Gender:
ALL
Ages:
Between 18 months and 29 years
Trial Updated:
02/14/2017
Locations: Broward General Medical Center Cancer Center, Fort Lauderdale, Florida +14 locations
Conditions: Leukemia
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Completed
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/10/2017
Locations: Pasco Pinellas Cancer Center - New Port Richey, New Port Richey, Florida +1 locations
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
Terminated
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2017
Locations: Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida
Conditions: Multiple Myeloma
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2016
Locations: Boehringer Ingelheim Investigational Site, Aventura, Florida +6 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining combination chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus rituximab in treating patients who h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Lymphoma
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Completed
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2016
Locations: Novartis Investigative Site, Tallahassee, Florida
Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas